71. The compound according to any one of Claims 41 and 68 to 71, wherein L^{1b} is a single bond,
L^{2b} is a single bond, a C_{1-6} alkylene group, a C_{2-6} alkenylene group or a C_{1-6} haloalkylene group (the C_{1-6} alkylene group, the C_{2-6} alkenylene group and the C_{1-6} haloalkylene group are unsubstituted or substituted with a hydroxy group or a cyano group),
the ring B^b is a C_{3-11} cycloalkane or a 4 to 7-membered non-aromatic heterocycle,
n^b is 0 or 1, and
R^{3b} is a hydroxy group, a C_{1-3} alkyl group or a C_{1-3} alkoxy group, a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

72. The compound according to any one of Claims 41 and 68 to 70, wherein L^{3b} is a single bond, and
R^{2b} is a hydrogen atom, a 4 to 7-membered non-aromatic heterocyclyl group, a phenyl group, a 5 to 10-membered aromatic heterocyclyl group or a 8 to 11-membered partially saturated aromatic cyclic group (the 4 to 7-membered non-aromatic heterocyclyl group, the phenyl group, the 5 to 10-membered aromatic heterocyclyl group and the 8 to 11-membered partially saturated aromatic cyclic group are unsubstituted or substituted with one or more identical or different substituents independently selected from the group consisting of hydroxy groups, amino groups, carbamoyl groups, sulfamoyl groups, halogen atoms, cyano groups, nitro groups, C_{1-6} alkyl groups (the C_{1-6} alkyl groups are unsubstituted or substituted with a cyano group), C_{1-6} haloalkyl groups, C_{3-11} cycloalkyl groups, C_{1-6} alkoxy groups, C_{1-6} haloalkoxy groups, C_{1-6} alkylthio groups, C_{1-6} haloalkylthio groups, C_{1-6} alkylsulfonyl groups, C_{1-6} haloalkylsulfonyl groups, C_{1-6} alkoxycarbonyl groups, 4 to 7-membered non-aromatic heterocyclyl groups, mono-C_{1-6} alkylamino groups, di-C_{1-6} alkylamino groups, phenyl groups, 5 to 6-membered aromatic heterocyclyl groups, mono-C_{1-6} alkylaminosulfonyl groups and di-C_{1-6} alkylaminosulfonyl groups), a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

73. The compound according to Claim 72, wherein R^{2b} is a hydrogen atom, a phenyl group, a 5 to 10-membered aromatic heterocyclyl group or a 8 to 11-membered partially saturated aromatic cyclic group (the phenyl group, the 5 to 10-membered aromatic heterocyclyl group and the 8 to 11-membered partially saturated aromatic cyclic group are unsubstituted or substituted with one, two or three identical or different substituents independently selected from the group consisting of halogen atoms, cyano groups, nitro groups, C_{1-3} alkyl groups, C_{1-3} haloalkyl groups and C_{1-6} alkoxycarbonyl groups), a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

74. The compound according to Claim 72, wherein R^{2b} is a 4 to 7-membered non-aromatic heterocyclyl group (the 4 to 7-membered non-aromatic heterocyclyl group is unsubstituted or substituted with one or two identical or different substituents independently selected from the group consisting of hydroxy groups, halogen atoms, cyano groups, C_{1-3} alkyl groups (the C_{1-3} alkyl groups are unsubstituted or substituted with a cyano group) and C_{1-3} haloalkyl groups), a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

75. The compound according to any one of Claims 41 and 68 to 71, wherein L^{3b} is represented by any of the following formulae (XIX^b-1) to (XIX^b-7):

71. The compound according to any one of Claims 41 and 68 to 70, wherein L^{1b} is a single bond,
L^{2b} is a single bond, a C_{1-6} alkylene group, a C_{2-6} alkenylene group or a C_{1-6} haloalkylene group (the C_{1-6} alkylene group, the C_{2-6} alkenylene group and the C_{1-6} haloalkylene group are unsubstituted or substituted with a hydroxy group or a cyano group),
the ring B^b is a C_{3-11} cycloalkane or a 4 to 7-membered non-aromatic heterocycle,
n^b is 0 or 1, and
R^{3b} is a hydroxy group, a C_{1-3} alkyl group or a C_{1-3} alkoxy group, a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

72. The compound according to any one of Claims 41 and 68 to 71, wherein L^{3b} is a single bond, and
R^{2b} is a hydrogen atom, a 4 to 7-membered non-aromatic heterocyclyl group, a phenyl group, a 5 to 10-membered aromatic heterocyclyl group or a 8 to 11-membered partially saturated aromatic cyclic group (the 4 to 7-membered non-aromatic heterocyclyl group, the phenyl group, the 5 to 10-membered aromatic heterocyclyl group and the 8 to 11-membered partially saturated aromatic cyclic group are unsubstituted or substituted with one or more identical or different substituents independently selected from the group consisting of hydroxy groups, amino groups, carbamoyl groups, sulfamoyl groups, halogen atoms, cyano groups, nitro groups, C_{1-6} alkyl groups (the C_{1-6} alkyl groups are unsubstituted or substituted with a cyano group), C_{1-6} haloalkyl groups, C_{3-11} cycloalkyl groups, C_{1-6} alkoxy groups, C_{1-6} haloalkoxy groups, C_{1-6} alkylthio groups, C_{1-6} haloalkylthio groups, C_{1-6} alkylsulfonyl groups, C_{1-6} haloalkylsulfonyl groups, C_{1-6} alkoxycarbonyl groups, 4 to 7-membered non-aromatic heterocyclyl groups, mono-C_{1-6} alkylamino groups, di-C_{1-6} alkylamino groups, phenyl groups, 5 to 6-membered aromatic heterocyclyl groups, mono-C_{1-6} alkylaminosulfonyl groups and di-C_{1-6} alkylaminosulfonyl groups), a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

73. The compound according to Claim 72, wherein R^{2b} is a hydrogen atom, a phenyl group, a 5 to 10-membered aromatic heterocyclyl group or a 8 to 11-membered partially saturated aromatic cyclic group (the phenyl group, the 5 to 10-membered aromatic heterocyclyl group and the 8 to 11-membered partially saturated aromatic cyclic group are unsubstituted or substituted with one, two or three identical or different substituents independently selected from the group consisting of halogen atoms, cyano groups, nitro groups, C_{1-3} alkyl groups, C_{1-3} haloalkyl groups and C_{1-6} alkoxycarbonyl groups), a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

74. The compound according to Claim 72, wherein R^{2b} is a 4 to 7-membered non-aromatic heterocyclyl group (the 4 to 7-membered non-aromatic heterocyclyl group is unsubstituted or substituted with one or two identical or different substituents independently selected from the group consisting of hydroxy groups, halogen atoms, cyano groups, C_{1-3} alkyl groups (the C_{1-3} alkyl groups are unsubstituted or substituted with a cyano group) and C_{1-3} haloalkyl groups), a tautomer or a pharmaceutically acceptable salt of the compound or a solvate thereof.

75. The compound according to any one of Claims 41 and 68 to 71, wherein L^{3b} is represented by any of the following formulae (XIX^b-1) to (XIX^b-7):